MedTrace Logo

ADX48621 for the Treatment of Levodopa Induced Dyskinesia in Patients With Parkinson's Disease

NCT01336088 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 83

Last updated 2012-07-16

No results posted yet for this study

Summary

The primary objective of the study is to evaluate the safety and tolerability of ADX48621 in Parkinson's disease patients following four weeks of dosing.

The secondary objectives of the study include the evaluation of the efficacy of ADX48621 compared with placebo in reducing levodopa induced dyskinesia in patients with Parkinson's; the evaluation of the effect of ADX48621 on symptoms of Parkinson's disease and patient ability to function, and the evaluation of the effect of coadministration of ADX48621 on L-dopa efficacy.

Conditions

Interventions

DRUG

ADX48621

oral administration

DRUG

Placebo

oral administration

Sponsors & Collaborators

  • Addex Pharma S.A.

    lead INDUSTRY

Principal Investigators

  • Addex Pharma · Addex Pharma

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2012-02-29
Completion
2012-02-29

Countries

  • United States
  • Austria
  • France
  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01336088 on ClinicalTrials.gov